|Table of Contents|

The correlation between EGFR gene mutation status and clinical pathological characteristics in patients with invasive lung adenocarcinoma accompanied by micropapillary and solid components

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 21
Page:
4077-4083
Research Field:
Publishing date:

Info

Title:
The correlation between EGFR gene mutation status and clinical pathological characteristics in patients with invasive lung adenocarcinoma accompanied by micropapillary and solid components
Author(s):
MEI Na1; LUO Yingbin1; WU Jianchun1; JIANG Lei2; TIAN Jianhui1; LI Yan1
1.Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200071,China;2.Shanghai Pulmonary Hospital,Shanghai 200433,China.
Keywords:
invasive lung adenocarcinoma; micropapillary; solid; EGFR gene mutation; clinicopathological characteristics
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.21.011
Abstract:
Objective:To investigate the EGFR gene mutation status in invasive lung adenocarcinoma with micropapillary and solid components and its clinicopathological characteristics.Methods:We retrospectively analyzed samples from 808 patients with invasive lung adenocarcinoma who were treated at the Shanghai Municipal Hospital of Traditional Chinese Medicine and Shanghai Pulmonary Hospital and underwent genetic testing from September 2018 to March 2023.The patients were categorized into the micropapillary/solid-positive group (MP/SD+) and micropapillary/solid-negative group (MP/SD-) according to the postoperative pathology results.Based on the proportions of solid and micropapillary components,the patients were categorized into three groups:MP/SD+ (<10%),MP/SD++ (10%~40%) and MP/SD+++ (>40%).The relationship of the gene mutation status with the MP/SD status and the clinicopathological characteristics was analyzed by SPSS26.0.Results:Among 808 patients,396 (49%) patients with the MP/SD components.The MP/SD status was related to the gender,smoking history,pleural invasion,lymphovascular invasion,STAS,tumor size,lymph node metastasis,TNM stage and EGFR mutation status.EGFR mutation was detected in 579 (71.7%) patients.The rate of EGFR mutation was 81.6% in the MP/SD-positive (323/396) group.The EGFR mutation rate in the (MP/SD+) group was higher than that in the (MP/SD-) group（P＜0.001）.The primary types of EGFR gene mutations were 19-del and L858R (90%).There was no significant difference among the three subgroups of MP/SD (P=0.510).Conclusion:The frequency of EGFR mutations in patients with lung adenocarcinoma with micropapillary and solid components was higher than that in patients with lung adenocarcinoma without micropapillary and solid components.group.The EGFR mutation rate in the (MP/SD+) group was higher than that in the (MP/SD-) group（P＜0.001）.The primary types of EGFR gene mutations were 19-del and L858R (90%).There was no significant difference among the three subgroups of MP/SD (P=0.510).Conclusion:The frequency of EGFR mutations in patients with lung adenocarcinoma with micropapillary and solid components was higher than that in patients with lung adenocarcinoma without micropapillary and solid components.

References:

［1］BADE BC,DELA CRUZ CS.Lung cancer 2020:Epidemiology,etiology,and prevention［J］.Clin Chest Med,2020,41(1):1-24.
［2］THAI AA,SOLOMON BJ,SEQUIST LV,et al.Lung cancer［J］.Lancet,2021,398(10299):535-554.
［3］TRAVIS WD,BRAMBILLA E,NOGUCHI M,et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma［J］.J Thorac Oncol,2011,6(2):244-285.
［4］KUHN E,MORBINI P,CANCELLIERI A,et al.Adenocarcinoma classification:patterns and prognosis［J］.Pathologica,2018,110(1):5-11.
［5］MOTONO N,MIZOGUCHI T,ISHIKAWA M,et al.Predictive value of recurrence of solid and micropapillary subtype in lung adenocarcinoma［J］.Oncology,2024,102(4):366-373.
［6］ARRIETA O,SALAS AA,CARDONA AF,et al.Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease［J］.Lung Cancer,2021,155:183-190.
［7］TRAVIS WD,BRAMBILLA E,NICHOLSON AG,et al.The 2015 world health organization classification of lung tumors:Impact of genetic,clinical and radiologic advances since the 2004 classification［J］.J Thorac Oncol,2015,10(9):1243-1260.
［8］ZHANG Y,ZHANG Y,HU Y,et al.Validation of the novel international association for the study of lung cancer grading system and prognostic value of filigree micropapillary and discohesive growth pattern in invasive pulmonary adenocarcinoma［J］.Lung Cancer,2023,175:79-87.
［9］OKUBO Y,KASHIMA J,TEISHIKATA T,et al.Prognostic impact of the histologic lepidic component in pathologic stage IA adenocarcinoma［J］.J Thorac Oncol,2022,17(1):67-75.
［10］TAKENO N,TARUMI S,ABE M,et al.Lung adenocarcinoma with micropapillary and solid patterns:Recurrence rate and trends［J］.Thorac Cancer,2023,14(30):2987-2992.
［11］LEE G,LEE HY,JEONG JY,et al.Clinical impact of minimal micropapillary pattern in invasive lung adenocarcinoma:prognostic significance and survival outcomes［J］.The American Journal of Surgical Pathology,2015,39(5):660-666.
［12］YANAGAWA N,SHIONO S,ABIKO M,et al.The clinical impact of solid and micropapillary patterns in resected lung adenocarcinoma［J］.Journal of Thoracic Oncology,2016,11(11):1976-1983.
［13］LI Y,BYUN AJ,CHOE JK,et al.Micropapillary and solid histologic patterns in N1 and N2 lymph node metastases are independent factors of poor prognosis in patients with stages Ⅱ to Ⅲ lung adenocarcinoma［J］.J Thorac Oncol,2023,18(5):608-619.
［14］CHOI SH,JEONG JY,LEE SY,et al.Clinical implication of minimal presence of solid or micropapillary subtype in early-stage lung adenocarcinoma［J］.Thorac Cancer,2021,12(2):235-244.
［15］DUMA N,SANTANA-DAVILA R,MOLINA JR. Non-small cell lung cancer:epidemiology,screening,diagnosis,and treatment［J］.Mayo Clin Proc,2019,94(8):1623-1640.
［16］LAI Y,ZHANG Z,LI J,et al.EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features［J］.Int J Mol Sci,2013,14(12):24549-24559.
［17］BATRA U,BISWAS B,PRABHASH K,et al.Differential clinicopathological features,treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer［J］.BMJ Open Respir Res,2023,10(1):e001492.
［18］CHAN KI,VONG HT,SIN LF,et al.Relationship between driver gene mutations,their relative protein expressions and survival in non-small cell lung carcinoma in Macao［J］.Clin Respir J,2018,12(4):1416-1423.
［19］眭玉霞,邓晓宇,伍铮,等.非小细胞肺癌驱动基因突变与临床病理特征的关系［J］.临床与实验病理学杂志,2020,36(09):1023-1028. MU YX,DENG XY,WU Z,et al.Comprehensive investigation of driver gene expression and clinicopathological characteristics in non-small cell lung cancer［J］.Chinese Journal of Clinical and Experimental Pathology,2020,36(09):1023-1028.
［20］刘宁,张康,颜淑霞,等.非小细胞肺癌EGFR基因突变及与疗效的相关性研究［J］.现代肿瘤医学,2013,21(02):330-333. LIU N,ZHANG K,YAN SX,et al.Non-small-cell lung carcinoma EGFR gene mutations and their association with therapeutic efficacy［J］.Modern Oncology,2013,21(02):330-333.
［21］BOUKANSA S,BENBRAHIM Z,GAMRANI S,et al.Correlation of epidermal growth factor receptor mutation with major histologic subtype of lung adenocarcinoma according to IASLC/ATS/ERS classification［J］.Cancer Control,2022,29:10732748221084930.
［22］WARTH A,PENZEL R,LINDENMAIER H,et al.EGFR,KRAS,BRAF and ALK gene alterations in lung adenocarcinomas:patient outcome,interplay with morphology and immunophenotype［J］.Eur Respir J,2014,43(3):872-883.
［23］ZHANG J,SUN J,ZHANG Z,et al.Driver mutation profiles and clinicopathological correlation in pulmonary adenocarcinoma with a micropapillary component［J］.Hum Pathol,2019,85:242-250.

Memo

Memo:
National Natural Science Foundation of China（No.82260535）;国家自然基金面上项目(编号:82174183);上海医学创新发展基金会中医药科技发展项目(编号： WL-LXBB-2021001K，WL-HBQN-2021009K);上海市进一步加快中医药传承创新发展三年行动计划 (2021年-2023年)(编号:ZY(2021-2023)-0211)
Last Update: 2024-09-30